The global anti-vascular endothelial growth factor therapeutics market is expected to generate $13,812.6 million revenue by 2030, advancing at a CAGR of 1.4% during 2021–2030. The rising prevalence of ocular disorders such as age-related macular degeneration (AMD), diabetic retinopathy (DR), macular edoema, and retinal vein occlusion, and the growing elderly population that increases the risk of developing several conditions, are the key factors driving the market. Moreover, new products in the pipeline either pending for approvals or in clinical trials are also expected to boost the market growth.
Moreover, the market has been witnessing the development of biosimilars of different anti-VEGF molecules for clinical use. For instance, ABP-938, a biosimilar candidate to Eylea of Amgen is under the phase-3 clinical trial; and FYB201, a biosimilar of Lucentis, manufactured by Formycon AG/Bioeq is under the BLA review accepted by the FDA.
The demand for Beovu is projected to witness the highest CAGR, of around 4%, throughout the forecast period. This growth can be attributed to its endorsement for use in 70 countries, with the approval received from the FDA in 2019 and from the EC in March 2022. Whereas, in 2021, the Eylea category held the largest market share and it is also predicted to maintain its market dominance throughout the projection period.
The APAC anti-vascular endothelial growth factor therapeutics market is expected to grow at the highest CAGR, of around 2%, during 2021–2030. In the region, Japan held the largest market share in 2021. Whereas, the Chinese market is expected to witness the fastest growth during the forecast period, owing to the approvals from the Chinese FDA for more than 30 clinical trials regarding conbercept.
Moreover, the Indian market is also expected to witness significant growth during the forecast period, and will become the second-fastest-growing market in the APAC region. This can be ascribed to the approval of new indications for intravitreal Aflibercept (EyleaTM) injection solution to treat DME by the Drugs Controller General of India (DCGI). Moreover, the high prevalence of retinal disorders across the country, a total of around 11 million patients in 2021, is necessitating the prolonged treatment with anti-VEGF injections.
On the other hand, the North American market accounted for the largest revenue share, of roughly 65%, in 2021, wherein the U.S. is the leader in the regional market.
In recent years, major companies have been involved in the development of new anti-VEGF medications to treat AMD and DR, among other diseases. For instance, Opthea developed OPT-302, which is currently undergoing phase-3 clinical trials. It is being developed to achieve broader inhibition of the VEGF family, along with its use in combination with anti-VEGF-A monotherapies, to demonstrate superior vision gains and enhance overall efficacy, over those achieved by inhibiting VEGF-A alone.
Major players in the anti-vascular endothelial growth factor therapeutics market include Biogen, F. Hoffmann-La Roche Ltd., CoherusBioSciences, Bausch Health Companies Inc., Viatris Inc., Pfizer Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Bayer AG, and Novartis AG.